Top

10-03-2025 | Nephrotic Syndrome | Guideline

A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy

Authors: Riku Hamada, Yoshitsugu Kaku, Aya Inaba, Hiroshi Kaito, Takahisa Kimata, Shuji Kondo, Mayumi Sako, Mai Sato, Keisuke Sugimoto, Seiji Tanaka, Yoshinobu Nagaoka, Kandai Nozu, Junya Hashimoto, Kenichiro Miura, Masaki Yamamoto, Fujimi Kawai, Shoichi Maruyama, Kenji Ishikura

Published in: Clinical and Experimental Nephrology

Excerpt

The Japanese Society for Pediatric Nephrology published the ‘‘Clinical Practice Guideline for Medical Treatment of Pediatric Idiopathic Nephrotic Syndrome (version 1.0) (in Japanese)’’ in 2005, and the ‘‘Clinical Practice Guideline for Pediatric Idiopathic Nephrotic Syndrome 2013″ [1, 2] in 2013. Under the supervision of the Japanese Society of Pediatric Nephrology, the Research for Intractable Renal Diseases of the Ministry of Health, Labour and Welfare of Japan have revised the guideline to include important evidence from 2013 that includes rituximab therapy and have published ‘‘Clinical Practice Guideline for Pediatric Idiopathic Nephrotic Syndrome 2020 (in Japanese)” (Shindan To Chiryo Sha, Inc., Tokyo, Japan) on September 30, 2020. Subsequently, an addendum to the guidelines was prepared and published on the Society’s website (in Japanese) on August 31, 2022. The committee herein published the digest of guideline in English, with an aim to introduce it to pediatricians around the world. …

Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol. 2015;19(1):6–33. https://doi.org/10.1007/s10157-014-1030-x.CrossRefPubMed

Kaku Y, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ishikura K, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy. Clin Exp Nephrol. 2015;19(1):34–53. https://doi.org/10.1007/s10157-014-1031-9.CrossRefPubMed

Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.

Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, van der Heijden AJ, Nauta J. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol. 2013;24(1):149–59. https://doi.org/10.1681/ASN.2012070646.CrossRefPubMed

Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int. 2015;87(1):217–24. https://doi.org/10.1038/ki.2014.240.CrossRefPubMed

Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87(1):225–32. https://doi.org/10.1038/ki.2014.260.CrossRefPubMed

Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015;2015(3):CD001533. https://doi.org/10.1002/14651858.CD001533.pub5.CrossRefPubMedPubMedCentral

Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr. 1992;120(5):721–5. https://doi.org/10.1016/s0022-3476(05)80234-3.CrossRefPubMed

Kaiser BA, Polinsky MS, Palmer JA, Dunn S, Mochon M, Flynn JT, Baluarte HJ. Growth after conversion to alternate-day corticosteroids in children with renal transplants: a single-center study. Pediatr Nephrol. 1994;8(3):320–5. https://doi.org/10.1007/BF00866347.CrossRefPubMed

10.

Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the international study of kidney disease in children. Lancet 1974; 2(7878):423–7.

11.

Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993;8(12):1326–32.PubMed

12.

Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58(1):317–24. https://doi.org/10.1046/j.1523-1755.2000.00168.x.CrossRefPubMed

13.

Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, Kaneko K, Yamashiro Y. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20(12):1744–9. https://doi.org/10.1007/s00467-005-2025-3.CrossRefPubMed

14.

Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, Shimizu T, Kaneko K. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2011;26(3):479–83. https://doi.org/10.1007/s00467-010-1707-7.CrossRefPubMed

15.

Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24(10):1689–97. https://doi.org/10.1681/ASN.2012121200.CrossRefPubMedPubMedCentral

16.

Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008;23(11):2013–20. https://doi.org/10.1007/s00467-008-0899-6.CrossRefPubMedPubMedCentral

17.

Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology (Carlton). 2016;21(1):21–7. https://doi.org/10.1111/nep.12537.CrossRefPubMed

18.

Basu B, Babu BG, Mahapatra TK. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children. Clin Exp Nephrol. 2017;21(1):143–51. https://doi.org/10.1007/s10157-016-1266-8.CrossRefPubMed

19.

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273–81. https://doi.org/10.1016/S0140-6736(14)60541-9.CrossRefPubMed

20.

Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308–15. https://doi.org/10.2215/CJN.09421010.CrossRefPubMedPubMedCentral

21.

Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl’Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26(9):2259–66. https://doi.org/10.1681/ASN.2014080799.CrossRefPubMedPubMedCentral

22.

Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K. Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol. 2022;33(2):401–19. https://doi.org/10.1681/ASN.2021050643.CrossRefPubMedPubMedCentral

23.

Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr. 2013;172(4):513–8. https://doi.org/10.1007/s00431-012-1913-3.CrossRefPubMed

24.

Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K. Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol. 2022;33(6):1193–207. https://doi.org/10.1681/ASN.2021111472.CrossRefPubMedPubMedCentral

25.

Li S, Yang H, Guo P, Ao X, Wan J, Li Q, Tan L. Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis. Oncotarget. 2017;8(42):73050–62. https://doi.org/10.18632/oncotarget.20377.CrossRefPubMedPubMedCentral

26.

Chiou YY, Lee YC, Chen MJ. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis. Curr Med Res Opin. 2017;33(8):1389–99. https://doi.org/10.1080/03007995.2017.1322567.CrossRefPubMed

27.

Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43(6):1377–84. https://doi.org/10.1038/ki.1993.194.CrossRefPubMed

28.

Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7(1):56–63. https://doi.org/10.1681/ASN.V7156.CrossRefPubMed

29.

Plank C, et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol. 2008;23(9):1483–93. https://doi.org/10.1007/s00467-008-0794-1.CrossRefPubMedPubMedCentral

30.

Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53(5):760–9. https://doi.org/10.1053/j.ajkd.2008.11.033.CrossRefPubMed

31.

Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P, Bagga A. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130–5. https://doi.org/10.1038/ki.2012.238.CrossRefPubMed

32.

Waldo FB, Benfield MR, Kohaut EC. Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol. 1998;12(5):397–400. https://doi.org/10.1007/s004670050473.CrossRefPubMed

33.

Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10(5):590–3. https://doi.org/10.1007/s004670050167.CrossRefPubMed

34.

Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D’Agati VD, Friedman AL. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868–78. https://doi.org/10.1038/ki.2011.195.CrossRefPubMedPubMedCentral

Title: A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy
Authors: Riku Hamada
Yoshitsugu Kaku
Aya Inaba
Hiroshi Kaito
Takahisa Kimata
Shuji Kondo
Mayumi Sako
Mai Sato
Keisuke Sugimoto
Seiji Tanaka
Yoshinobu Nagaoka
Kandai Nozu
Junya Hashimoto
Kenichiro Miura
Masaki Yamamoto
Fujimi Kawai
Shoichi Maruyama
Kenji Ishikura
Publication date: 10-03-2025
Publisher: Springer Nature Singapore
Keywords: Nephrotic Syndrome
Glucocorticoid
Mycophenolate Mofetil
Rituximab
Rituximab
Prednisolone
Published in: Clinical and Experimental Nephrology
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-025-02636-5

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Podcast | Sexual health in older age

Springer Medicine

Excerpt

Please log in to get access to this content

Elevate your expertise in aplastic anemia (Link opens in a new window)

Keynote series | Spotlight on menopause